Reflections of a HIV advocate: ‘Why I’ll keep showing up to protest Gilead’s pricing on Hepatitis C drugs’

November 11, 2014


Globally an estimated 185 million people have Hepatitis C (HCV). Each year, nearly 500,000 die of HCV-related complications. But Hepatitis C is curable with the right treatment. However life-saving treatment, sofosbuvir (Sovaldi) and lepidasvir can only be just that if it is affordable, accessible and available to the millions of people who need it. Gilead has priced sofosbuvir at US$84,000 for a 12-week course of treatment. Gilead controls generic competition, and though it recently announced a voluntary licensing agreement with Indian drug manufacturers, patents and licensing regulations continue to block access for those in high –income and middle income countries, where 46% of those needing treatment live. This excludes 73 million people from access to affordable life-saving treatment. Hep C activists are organizing, agitating and taking action to demand access to new life-saving hepatitis C virus meds, from community based organisations in India filing patent oppositions, to global advocates forming a Hep C World Community Advisory Board to develop global strategies.


Loon Gangte, the International Treatment Preparedness Coalition (ITPC) South Asia Regional Coordinator and other local activists staged a direct action at Gilead’s recent press conference in New Delhi. Here are his reflections.



Photo Credit: Shailly Gupta, MSF


We knew it wasn’t going to be easy to protest at the recent Gilead Press Conference in New Delhi, held on 15th September 2014. The press conference was in a posh, five-star hotel. So we thought we’d do a silent protest, to get our message across to Gilead, Indian pharmaceutical companies and the local press that Gilead’s refusal to allow generic versions of the drug Solvadi (which can cure Hepatitis C) in some countries is unacceptable.


We were a group of local activists, from across organizations in India, numbering about 10 people. When we arrived at the hotel, we found the press conference room and set-up the protest at the entrance. We pulled out a large banner, and sat down at the main entrance gate. We did not shout or make noise – we just stood there in our HIV Positive t-shirts with our posters. After about 30 minutes, the security men said, ‘that’s enough’ and told us to take down our banner and leave. We politely refused. Suddenly, I saw two of my colleagues from the Delhi Network of Positive People (DNP+) being manhandled by security as they attempted to drag them out of the room.  

I didn’t think this was right, so I ran towards them and wrapped my body around them, locking our hands and feet together and forming a kind of human chain. Now the security men tried to pull us out of the room one by one, but we were too strong to break apart. They called for more men, and gradually because they greatly outnumbered us started lifting us off the floor. I had been silent, but now I began to yell, ‘Why are you doing this? We are here fighting for our lives.’

As I was yelling, about five men descended upon me and yanked me out of the room by my hair. They threw me on the ground outside of the exit gate. I was stunned, and angry. I found out later that someone from the press conference barred journalists from taking photographs or shooting videos of the protestors outside the venue.

Looking back, despite the physical harm, I’m still proud that we pulled off the protest. At the Delhi Network of Positive People (DNP+) and ITPC South Asia, we don’t use protests as the first option for conveying our message. But if repeated letters and meetings have no effect – as is the result with Gilead, who refuses to engage with us – then we have to take our campaign public. We show up for a protest because we have no other options.

But despite Gilead’s attempts to cover up our protests, we are not going anywhere. The HIV treatment movement cannot ignore Hepatitis C; we have seen more and more people diagnosed with the disease among our friends. We have watched them suffer or die because they cannot afford the cost of treatment. Now that there is a cure for Hepatitis C on the market, we have even more incentive to fight to access it – otherwise all of our hard work and investment in HIV treatment will be in vain.

To keep up-to-date with the work of ITPC network members, join their mailing list or follow them on Facebook or Twitter


Join HIV Advocates online for advocacy resources, news, and advice.

Like our facebook page:


Follow us on Twitter:!/HIVadvocates


Follow us on Pinterest:


Or Join us on Sina Weibo: